Novartis Oncology helps cancer patients have long-term access to life-extending therapies through its Glivec International Patient Assistance Program (GIPAP), one of the most comprehensive and far-reaching cancer patient access programs ever implemented on a global scale.
Since its introduction in 2002, GIPAP has provided the breakthrough treatment Glivec (imatinib) at cost to more than 35,000 cancer patients in more than 80 countries. Glivec is a proven-effective treatment for Philadelphia positive chronic myeloid leukemia (Ph+CML) and gastrointestinal stromal tumor (GIST). GIPAP and the Novartis Oncology Program (NOA) have helped provide Glivec to over 1,400 socially disadvantaged Filipino cancer patients.
From 2006 to 2008 alone, benefits provided by the NOA program to Filipino patients are valued at over P2 billion. This innovative program is being implemented in more than 65 participating centers across the archipelago. Today, GIPAP has evolved into the broader NOA program which continues to serve Filipino patients already enrolled in GIPAP and an additional 120-plus more nationwide.
Another life-saving treatment developed by Novartis Oncology is Exjade (deferasirox). Exjade is used for the treatment of chronic iron overload due to frequent blood transfusions in patients aged six and older with beta thalassemia major. This is an inherited blood disorder that causes severe anemia and bone deformities. Untreated, it can lead to death before the age of 20.
Novartis is exploring ways to increase Filipino patients’ access to thalassemia treatments.